Eli Lilly (LLY) Receivables (2009 - 2026)

Eli Lilly (LLY) has reported Receivables for 18 consecutive years, with $21.2 billion the latest figure, recorded in Q1 2026.

• Receivables for Q1 2026 came in at $21.2 billion, up 51.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.2 billion (up 51.23% YoY), and the FY2025 annual result was $20.2 billion, up 51.82% from the prior year.
• Receivables was $21.2 billion for Q1 2026 at Eli Lilly, up from $20.2 billion in the prior quarter.
• Over five years, Receivables peaked at $21.2 billion in Q1 2026 and troughed at $7.7 billion in Q2 2022.
• Average Receivables over 5 years is $12.5 billion, with a median of $11.3 billion recorded in 2023.
• Year-over-year, Receivables advanced 5.31% in 2022 and surged 61.45% in 2025.
• Over 5 years, Receivables stood at $8.6 billion in 2022, then surged by 32.45% to $11.3 billion in 2023, then rose by 17.11% to $13.3 billion in 2024, then soared by 51.82% to $20.2 billion in 2025, then gained by 5.07% to $21.2 billion in 2026.
• Per Business Quant data, the three most recent Receivables figures were $21.2 billion in Q1 2026, $20.2 billion in Q4 2025, and $19.5 billion in Q3 2025.